Study in Patients With Asthma
Phase 2
Completed
- Conditions
- Asthma
- Registration Number
- NCT00215410
- Lead Sponsor
- Dey
- Brief Summary
The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Children with a history of asthma
- Written guardian approval
Exclusion Criteria
- Current or recent asthma exacerbation, requiring hospitalization
- History of smoking
- Debilitating or systemic and/or life-threatening diseases.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Measure of lung function
- Secondary Outcome Measures
Name Time Method Change in lung function, as well as vital signs Physical Exam results, AE reporting, etc
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does the investigational drug target in asthma patients compared to standard-of-care treatments in NCT00215410?
How does the efficacy of the investigational drug in NCT00215410 compare to corticosteroids and bronchodilators in moderate to severe asthma?
What biomarkers were used in NCT00215410 to identify asthma subtypes and predict treatment response in phase 2 trials?
What adverse events were reported in NCT00215410 and how do they compare to known side effects of asthma medications like LABAs and ICSs?
Are there combination therapies or competitor drugs in development for asthma that build on findings from NCT00215410 phase 2 trials?
Trial Locations
- Locations (1)
Research Site
🇺🇸Houston, Texas, United States
Research Site🇺🇸Houston, Texas, United States